AR054441A1 - Derivados de aminoacidos - Google Patents
Derivados de aminoacidosInfo
- Publication number
- AR054441A1 AR054441A1 ARP060101665A ARP060101665A AR054441A1 AR 054441 A1 AR054441 A1 AR 054441A1 AR P060101665 A ARP060101665 A AR P060101665A AR P060101665 A ARP060101665 A AR P060101665A AR 054441 A1 AR054441 A1 AR 054441A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- aryl
- oxymethyl
- amino
- Prior art date
Links
- 150000003862 amino acid derivatives Chemical class 0.000 title 1
- -1 oxycarbonyloxy Chemical group 0.000 abstract 24
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000003118 aryl group Chemical group 0.000 abstract 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 125000001153 fluoro group Chemical group F* 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000012453 solvate Substances 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- PNYZSYOQKIXTEL-QMMMGPOBSA-N (2s)-2-amino-3-cyclobutyl-2-methylpropanoic acid Chemical compound OC(=O)[C@](N)(C)CC1CCC1 PNYZSYOQKIXTEL-QMMMGPOBSA-N 0.000 abstract 1
- ASDHRKWLZHKRQV-VIFPVBQESA-N (2s)-2-amino-3-cyclopentyl-2-methylpropanoic acid Chemical compound OC(=O)[C@](N)(C)CC1CCCC1 ASDHRKWLZHKRQV-VIFPVBQESA-N 0.000 abstract 1
- WDAMHXABMOPUPC-VIFPVBQESA-N (2s)-2-amino-4-ethyl-2-methylhexanoic acid Chemical compound CCC(CC)C[C@](C)(N)C(O)=O WDAMHXABMOPUPC-VIFPVBQESA-N 0.000 abstract 1
- ZIMXPVDWRPAZJL-JTQLQIEISA-N (2s)-2-amino-5-ethyl-2-methylheptanoic acid Chemical compound CCC(CC)CC[C@](C)(N)C(O)=O ZIMXPVDWRPAZJL-JTQLQIEISA-N 0.000 abstract 1
- VHWJJTKKTVOZNB-APPZFPTMSA-N (2s,5r)-2-amino-2,5-dimethylheptanoic acid Chemical compound CC[C@@H](C)CC[C@](C)(N)C(O)=O VHWJJTKKTVOZNB-APPZFPTMSA-N 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 abstract 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 abstract 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 abstract 1
- 235000008206 alpha-amino acids Nutrition 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000005366 cycloalkylthio group Chemical group 0.000 abstract 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Reivindicacion 1: Un método para tratar el dolor en un mamífero, incluyendo un ser humano, que incluye la administracion a dicho mamífero de una cantidad eficaz de un compuesto de formula (1), o una sal farmacéuticamente aceptable o solvato del mismo, donde: R1 es alquilo C1-6, estando dicho alquilo C1-6 opcionalmente sustituido con uno o más grupos halo, -R5, -OR5 o.-SR5; R2 es metilo, opcionalmente sustituido con uno o más grupos fluor; R3 es H, alquilo C1-6, arilo, indanilo o (alquilC1- 6)oxicarboniloxi(alquiloC1-6); R4 es H, alquilC1-6-C(O)-, aril-C(O)-, o un resto de un alfa-aminoácido natural unido a través de su grupo carboxilo para formar una amida; R5 es alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-8 o arilo; arilo es fenilo o naftilo, cada uno opcionalmente sustituido con uno o más sustituyentes seleccionados entre halo, -NR6R6, alquilo C1-6, cicloalquilo C3-8, alcoxi C1-6 y ciano; y R6 es H, alquilo C1-6 o cicloalquilo C3-8. Reivindicacion 2: Un compuesto de formula (2), o una sal farmacéuticamente aceptable o solvato del mismo, donde: R7 es: a) alquilo 6-10 ramificado, distinto de 4-metilpent-1-ilo y 1-metilpent-1-ilo; b) alquilo C2-6 sustituido con uno o más grupos fluor, distinto de 1-fluoroet-1-ilo, heptafluoropropilo, 2,2-ditrifluorometilet-1-ilo, pentafluoroetilo, 2-fluoroet-1-ilo, 2-fluoropent-2-ilo y 2-fluoro-3-metilbut-1-ilo; c) alquilo C1-6 sustituido con un grupo cicloalquilo C3-8, distinto de ciclohexilmetilo; d) etilo sustituido con un grupo arilo, distinto de cuando arilo es fenilo o fenilo sustituido con un grupo -NH2, yodo o metoxi (sin tener en cuenta otra sustitucion); e) alquilo C3-4 sustituido con arilo, distinto de cuando arilo es fenilo, 3,4-dihidroxifenilo o 3,4- dimetoxifenilo; d) alquilo C5-6 sustituido con arilo; g) alquilo C1-2 sustituido con alcoxi C5-6; h) alquilo C3-6 sustituido con alcoxi C1-6; i) alquilo C1-6 sustituido con cicloalquiloxi C3-8; j) alquilo C1-6 sustituido con ariloxi, distinto de (2- metoxifenil) oximetilo, (4-metoxifenil)oximetilo, (4-clorofenil)oximetilo, (2,6-dimetilfenil)oximetilo, (2-metoxi-5-clorofenil)oximetilo, (2-metoxi-5-fluorofenil) oximetilo y (2-metoxi-4-clorofenil)oximetilo; k) metilo sustituido con hexiltio o alquilo C4-6 sustituido con alquiltio C1-6; l) alquilo C1-6 sustituido con cicloalquiltio C3-8, distinto de ciclohexiltiometilo; o m) alquilo C1-6 sustituido con ariltio, distinto de feniltiometilo, (4-clorofenil)tiometilo, (4- fluorofenil)tiometilo, 2-(feniltio)etilo, (4-clorofenil)tioetilo, (4-metoxifenil)tiometilo y (4-metoxifenil)tioetilo; R8 es metilo, opcionalmente sustituido con uno o más grupos fluor; arilo es fenilo o naftilo, cada uno opcionalmente sustituido con uno o más sustituyentes seleccionados entre halo, -NR9R9, alquilo C1-6, cicloalquilo C3-8, alcoxi C1-6 y ciano; y R9 es H, alquilo C1-6 o cicloalquilo C3-8. Reivindicacion 5: Un compuesto de formula (2) de acuerdo con una cualquiera de las reivindicaciones 2 a 4, donde el compuesto se selecciona entre: ácido (2S)-2-amino-4-etil-2-metilhexanoico; ácido (2S)-2-amino-4-etil-2-metilhexanoico benceno; 2,5,5-trimetil-L-norleucina; ácido (2S)-2-amino-3-ciclopentil-2-metilpropanoico; ácido (2S)-2-amino-5-etil-2- metilheptanoico; ácido (2S)-2-amino-3-ciclobutil-2-metilpropanoico; y ácido (2S,5R)-2-amino-2,5-dimetilheptanoico; o una sal farmacéuticamente aceptable o solvato del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67602505P | 2005-04-28 | 2005-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054441A1 true AR054441A1 (es) | 2007-06-27 |
Family
ID=36677128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101665A AR054441A1 (es) | 2005-04-28 | 2006-04-26 | Derivados de aminoacidos |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7612226B2 (es) |
| EP (1) | EP1879567A1 (es) |
| JP (2) | JP4173909B1 (es) |
| KR (1) | KR100925900B1 (es) |
| CN (1) | CN101166524B (es) |
| AP (1) | AP2007004161A0 (es) |
| AR (1) | AR054441A1 (es) |
| AU (1) | AU2006238933B2 (es) |
| BR (1) | BRPI0609879A2 (es) |
| CA (1) | CA2606353C (es) |
| CR (1) | CR9472A (es) |
| DO (1) | DOP2006000095A (es) |
| EA (1) | EA200701852A1 (es) |
| GT (1) | GT200600178A (es) |
| HK (1) | HK1116417A1 (es) |
| IL (1) | IL185790A0 (es) |
| MA (1) | MA29408B1 (es) |
| MX (1) | MX2007010978A (es) |
| NL (1) | NL1031705C2 (es) |
| NO (1) | NO20076000L (es) |
| PE (1) | PE20061435A1 (es) |
| SV (1) | SV2008002512A (es) |
| TN (1) | TNSN07400A1 (es) |
| TW (1) | TW200719889A (es) |
| UY (1) | UY29498A1 (es) |
| WO (1) | WO2006114707A1 (es) |
| ZA (1) | ZA200707678B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1094757C (zh) | 1996-07-24 | 2002-11-27 | 沃尼尔·朗伯公司 | 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物 |
| BRPI0609879A2 (pt) * | 2005-04-28 | 2010-05-11 | Pfizer Ltd | derivados de aminoácidos |
| CA2625572A1 (en) * | 2005-11-17 | 2007-05-24 | Pfizer Limited | Amino acid derivatives |
| WO2008031221A1 (en) * | 2006-09-12 | 2008-03-20 | Cephalin Pharmaceuticals Inc. | Isovaline for treatment of pain |
| CN101195583B (zh) * | 2006-12-04 | 2012-07-04 | 四川抗菌素工业研究所有限公司 | 一种光学纯米那普仑及其盐的制备方法 |
| UA107561C2 (xx) * | 2008-09-09 | 2015-01-26 | Поліморфні форми ацилсульфонамідів | |
| JP2012176902A (ja) * | 2011-02-25 | 2012-09-13 | Tosoh F-Tech Inc | 新規な光学活性含フッ素化合物、その製造方法及びそれを用いた光学活性３，３，３−トリフルオロアラニンの製造方法 |
| AT514349B1 (de) * | 2013-06-12 | 2018-05-15 | Red Bull Gmbh | Alpha-alkylierte Aminosäuren (AAAAs) |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB504209A (en) | 1937-12-14 | 1939-04-21 | Pirelli General Cable Works | Improvements in or relating to electric cables |
| BR6239521D0 (pt) * | 1961-08-09 | 1973-06-14 | Merck & Co Inc | Processo de preparacao de novos amino acidos |
| FR2586562B1 (fr) | 1985-09-02 | 1989-03-10 | Inst Nat Sante Rech Med | Composition pharmaceutique contenant de l'a-methylhistamine |
| DE3811256A1 (de) | 1988-04-02 | 1989-10-19 | Hoechst Ag | (alpha)-trifluormethylaminosaeure-derivate, verfahren zur herstellung von (alpha)-trifluormethylaminosaeure-derivaten und ihre verwendung als arzneimittel |
| EP0484437A4 (en) | 1989-07-27 | 1994-06-01 | Searle & Co | Renal-selective prodrugs for the treatment of hypertension |
| FR2681067B1 (fr) * | 1991-09-10 | 1993-12-17 | Elf Sanofi | Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant. |
| JPH042899A (ja) | 1990-04-16 | 1992-01-07 | Arakawa Chem Ind Co Ltd | 紙用サイズ剤および該サイズ剤を用いる紙サイジング方法 |
| FR2661909B1 (fr) | 1990-05-09 | 1997-08-14 | Inst Nat Sante Rech Med | Nouveaux composes agonistes du recepteur h3 de l'histamine a usage therapeutique, compositions pharmaceutiques agissant comme agonistes dudit recepteur et procede de preparation. |
| JPH051002A (ja) | 1991-02-15 | 1993-01-08 | Nikko Kyodo Co Ltd | α−アミノ酸の製造方法 |
| CA2068038A1 (en) | 1991-05-08 | 1992-11-09 | Christopher Yee | Enzymatic resolution of .alpha.-tertiary carboxylic acid esters |
| US5993775A (en) * | 1991-11-27 | 1999-11-30 | Diatide, Inc. | Radioactively labeled peptides comprising a single thiol moiety |
| GB9200210D0 (en) | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
| US5786373A (en) | 1992-10-14 | 1998-07-28 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5362747A (en) | 1992-11-25 | 1994-11-08 | Abbott Laboratories | 2-nitroaryl and 2-cyanoaryl compounds as regulators of nitric oxide synthase |
| GB9325368D0 (en) | 1993-12-10 | 1994-02-16 | Univ Bristol | Organic compounds |
| GB9325360D0 (en) | 1993-12-10 | 1994-02-16 | Univ Bristol | Organic compounds |
| IS4261A (is) | 1994-02-21 | 1995-08-22 | Astra Aktiebolag | Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra |
| DE19533617A1 (de) | 1995-09-11 | 1997-03-13 | Degussa | Neues Verfahren zur Herstellung von optisch aktiven alpha-Aminosäuren und alpha-Aminosäure-Derivaten |
| DK0780386T3 (da) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
| WO1998014208A1 (en) | 1996-09-30 | 1998-04-09 | President And Fellows Of Harvard College | Reactive ligands and covalent ligand-protein complexes |
| US5962523A (en) | 1996-10-25 | 1999-10-05 | Discovery Laboratories, Inc. | Methods of using butyric acid derivatives to protect against hair loss |
| JPH10333511A (ja) | 1997-05-30 | 1998-12-18 | Ricoh Co Ltd | 画像除去促進液、該画像除去促進液を用いた被記録材の再生方法及び再生装置 |
| JP4205191B2 (ja) | 1997-12-26 | 2009-01-07 | ダイセル化学工業株式会社 | α−アミノニトリル誘導体及びα−アミノ酸の製造方法 |
| AU2747199A (en) | 1998-03-11 | 1999-09-27 | Kabushiki Kaisha Soken | Skin normalizing agents |
| EP1071655A1 (en) * | 1998-04-17 | 2001-01-31 | Kenneth Curry | Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation |
| EP1140945B1 (en) | 1998-12-18 | 2003-06-04 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| AU1857600A (en) | 1998-12-22 | 2000-07-12 | Neurosearch A/S | Ion channel modulating agents |
| FR2788271B1 (fr) | 1999-01-07 | 2001-02-09 | Rhone Poulenc Agrochimie | Nouveau procede de preparation d'aminoacides chiraux |
| WO2000043352A1 (en) | 1999-01-22 | 2000-07-27 | Pharmacore, Inc. | A method for the synthesis of compounds of formula 1 and derivatives thereof |
| CN1343219A (zh) | 1999-01-28 | 2002-04-03 | 中外制药株式会社 | 取代的苯乙基胺衍生物 |
| FR2791982B1 (fr) | 1999-04-06 | 2002-12-27 | Inst Nat Sante Rech Med | Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques. |
| WO2001009117A1 (en) * | 1999-07-29 | 2001-02-08 | Allellix Neuroscience Inc. | Tricyclic compounds as glycine transport inhibitors |
| FR2796943A1 (fr) | 1999-07-30 | 2001-02-02 | Aventis Pharma Sa | Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique |
| KR100876753B1 (ko) | 1999-09-07 | 2009-01-07 | 가부시끼가이샤 소껭 | 피부 건전화제 |
| EP1219593A4 (en) | 1999-09-07 | 2004-09-01 | Mitsubishi Rayon Co | METHOD FOR PRODUCING AN OPTICALLY ACTIVE AMINAL ALCOHOL |
| JP2001081013A (ja) | 1999-09-10 | 2001-03-27 | Soken Kk | 毛髪健全化剤 |
| US7300775B2 (en) | 1999-12-29 | 2007-11-27 | Verenium Corporation | Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents |
| US6656958B2 (en) * | 2000-02-02 | 2003-12-02 | Abbott Laboratories | Substituted pyridine compounds useful for controlling chemical synaptic transmission |
| DE10121028A1 (de) | 2000-05-05 | 2002-01-31 | Basf Ag | Verfahren zur Herstellung von Aldehyden |
| DE10121026A1 (de) | 2000-05-05 | 2002-02-07 | Basf Ag | Verfahren zur Herstellung von Aldehyden |
| EP1300392B1 (en) | 2000-05-18 | 2012-09-05 | Mitsubishi Rayon Co., Ltd. | Process for producing optically active alpha-amino acid and optically active alpha-amino acid amide |
| WO2003011799A1 (en) | 2000-07-31 | 2003-02-13 | Brandeis University | Kinetic resolutions of chirat 3- and 3-substituted carboxylic acids |
| DE10048715A1 (de) * | 2000-09-30 | 2004-05-19 | Grünenthal GmbH | Verwendung von Aminosäure zur Behandlung von Schmerz |
| AUPR406901A0 (en) | 2001-03-29 | 2001-04-26 | La Trobe University | Insecticide and method of controlling insects |
| JP4715058B2 (ja) | 2001-08-02 | 2011-07-06 | Ｊｓｒ株式会社 | 感放射性樹脂組成物 |
| JP2003221328A (ja) | 2002-01-29 | 2003-08-05 | Soken Kk | 皮膚健全化剤 |
| JP2005538950A (ja) | 2002-05-15 | 2005-12-22 | ジェンザイム、コーポレーション | ２−アルキルシステイン、２−（ヒドロキシル化フェニル）−４−アルキルチアゾリン−４−カルボン酸およびそれらの誘導体の合成 |
| US20060014805A1 (en) | 2002-08-01 | 2006-01-19 | Markus Kordes | Pesticidal fluoroalkene derivatives |
| WO2004024709A2 (en) * | 2002-09-13 | 2004-03-25 | Prescient Neuropharma Inc. | Xanthenyl cubane analogs with activity at the metabotropic glutamate receptors |
| AU2003289242A1 (en) | 2003-01-10 | 2004-08-10 | Kaneka Corporation | PROCESS FOR PRODUCING OPTICALLY ACTIVE Alpha-METHYLCYSTEINE DERIVATIVE |
| JP2005060311A (ja) * | 2003-08-13 | 2005-03-10 | Mochida Pharmaceut Co Ltd | Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤 |
| GB0322140D0 (en) * | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| JPWO2005044780A1 (ja) | 2003-11-10 | 2007-05-17 | 杏林製薬株式会社 | アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤 |
| US20090215895A1 (en) * | 2004-01-30 | 2009-08-27 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| GB0405289D0 (en) | 2004-03-09 | 2004-04-21 | Novartis Ag | Organic compounds |
| TW200642687A (en) * | 2005-03-01 | 2006-12-16 | Pfizer Ltd | Combinations comprising α-2-δ ligands |
| CA2599662A1 (en) | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of pde7 inhibitors for the treatment of neuropathic pain |
| CA2601508C (en) * | 2005-03-17 | 2012-01-03 | Pfizer, Inc. | Cyclopropanecarboxamide derivatives |
| BRPI0609879A2 (pt) * | 2005-04-28 | 2010-05-11 | Pfizer Ltd | derivados de aminoácidos |
| CA2631535C (en) * | 2005-12-02 | 2010-07-27 | Pfizer Limited | Spirocyclic quinazoline derivatives as pde7 inhibitors |
-
2006
- 2006-04-19 BR BRPI0609879-7A patent/BRPI0609879A2/pt not_active Application Discontinuation
- 2006-04-19 KR KR1020077024860A patent/KR100925900B1/ko not_active IP Right Cessation
- 2006-04-19 MX MX2007010978A patent/MX2007010978A/es active IP Right Grant
- 2006-04-19 JP JP2008508341A patent/JP4173909B1/ja not_active Expired - Fee Related
- 2006-04-19 CN CN2006800141982A patent/CN101166524B/zh not_active Expired - Fee Related
- 2006-04-19 CA CA2606353A patent/CA2606353C/en not_active Expired - Fee Related
- 2006-04-19 AP AP2007004161A patent/AP2007004161A0/xx unknown
- 2006-04-19 EA EA200701852A patent/EA200701852A1/ru unknown
- 2006-04-19 EP EP06727559A patent/EP1879567A1/en not_active Withdrawn
- 2006-04-19 WO PCT/IB2006/001086 patent/WO2006114707A1/en active Application Filing
- 2006-04-19 AU AU2006238933A patent/AU2006238933B2/en not_active Ceased
- 2006-04-25 PE PE2006000431A patent/PE20061435A1/es not_active Application Discontinuation
- 2006-04-26 DO DO2006000095A patent/DOP2006000095A/es unknown
- 2006-04-26 AR ARP060101665A patent/AR054441A1/es not_active Application Discontinuation
- 2006-04-26 UY UY29498A patent/UY29498A1/es not_active Application Discontinuation
- 2006-04-27 TW TW095115092A patent/TW200719889A/zh unknown
- 2006-04-27 NL NL1031705A patent/NL1031705C2/nl not_active IP Right Cessation
- 2006-04-27 GT GT200600178A patent/GT200600178A/es unknown
- 2006-04-28 US US11/414,422 patent/US7612226B2/en not_active Expired - Fee Related
- 2006-04-28 SV SV2006002512A patent/SV2008002512A/es not_active Application Discontinuation
-
2007
- 2007-09-06 ZA ZA200707678A patent/ZA200707678B/xx unknown
- 2007-09-06 IL IL185790A patent/IL185790A0/en unknown
- 2007-10-25 CR CR9472A patent/CR9472A/es unknown
- 2007-10-26 TN TNP2007000400A patent/TNSN07400A1/fr unknown
- 2007-10-26 MA MA30323A patent/MA29408B1/fr unknown
- 2007-11-21 NO NO20076000A patent/NO20076000L/no not_active Application Discontinuation
-
2008
- 2008-06-18 HK HK08106675.1A patent/HK1116417A1/xx not_active IP Right Cessation
- 2008-07-02 JP JP2008173198A patent/JP2009040767A/ja not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054441A1 (es) | Derivados de aminoacidos | |
| PE20040349A1 (es) | Beta-aminoacidos con afinidad por la proteina alfa-2-delta | |
| AR049291A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| AR046660A1 (es) | Metodo de tratamiento de la ateroesclerosis | |
| AR051293A1 (es) | Inhibidores bace | |
| AR033620A1 (es) | Compuestos de sulfonilo de alfa-aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| AR084768A1 (es) | Moduladores de la senda de complemento y usos de los mismos | |
| AR055283A1 (es) | Inhibidores de cisteinproteasa de catepsina | |
| AR077701A1 (es) | Compuestos antiproliferativos, conjugados de los mismos, procedimientos para estos, y usos de los mismos | |
| AR078944A1 (es) | Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa | |
| EA200501098A1 (ru) | Антибактериальные агенты | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
| AR038383A1 (es) | Compuesto inhibidor de la hepatitis c | |
| AR043049A1 (es) | Derivados de hidantoina, proceso de preparacion del mismo y composicion farmaceutica | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| CO6351777A2 (es) | Compuestos de tetraciclina sustituidod con fluor en c7 | |
| EA200701810A1 (ru) | Производное изоксазолина и новый способ его получения | |
| AR079130A1 (es) | Compuestos inhibidores de la hepatitis c | |
| ES2557477T3 (es) | Nuevos compuestos peptídicos cíclicos | |
| AR055297A1 (es) | Ligandos moduladores de los receptores rars, utilizacion en medicina humana asi como en cosmetica | |
| PE20040666A1 (es) | Derivados novedosos de piperidina | |
| PE20040907A1 (es) | Derivados de anilinopirazol | |
| CO5680413A2 (es) | Aminoacidos con afinidad por la proteina c2 delta | |
| AR043444A1 (es) | Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |